NSRX

Nasus Pharma Ltd

Apr 01 • 10:27AM ET

2.30

+0.08 3.60 %

Healthcare • Drug Manufacturers - General • Israel • AMEX

Index	-	P/E	-	EPS (ttm)	-0.19	Insider Own	66.02%	Shs Outstand	9.02M	Perf Week	-16.67%
Market Cap	19.80M	Forward P/E	-	EPS next Y	-1.79	Insider Trans	0.26%	Shs Float	2.93M	Perf Month	-51.58%
Enterprise Value	18.48M	PEG	-	EPS next Q	-0.19	Inst Own	0.03%	Short Float	0.39%	Perf Quarter	-70.47%
Income	-1.74M	P/S	-	EPS this Y	-92.86%	Inst Trans	-0.06%	Short Ratio	0.07	Perf Half Y	-65.41%
Sales	0.00M	P/B	23.87	EPS next Y	-10.49%	ROA	-	Short Interest	0.01M	Perf YTD	-74.86%
Book/sh	0.10	P/C	14.56	EPS next 5Y	-17.13%	ROE	-	52W High	9.99 -76.98%	Perf Year	-
Cash/sh	0.16	P/FCF	-	EPS past 3/5Y	-49.37% -	ROIC	-195.22%	52W Low	1.98 16.16%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	11.97% 11.04%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	0.45	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.24	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	33.29	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.24	EPS Q/Q	-	SMA20	-29.65%	Beta	-	Target Price	20.00
Payout	-	Debt/Eq	0.05	Sales Q/Q	-	SMA50	-51.03%	Rel Volume	0.35	Prev Close	2.22
Employees	7	LT Debt/Eq	0.02	Earnings	Dec 03	SMA200	-65.06%	Avg Volume	168.94K	Price	2.30
IPO	Aug 13, 2025	Option/Short	No / Yes	EPS/Sales Surpr.	33.33% -	Trades		Volume	11,284	Change	3.60%

Mar-25-26 09:00AM	Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update (GlobeNewswire) +10.84%
Mar-16-26 07:30AM	Nasus Pharma Announces Positive Top Line Data from Phase 2 Clinical Study of NS002: Achieves Significantly Superior and Faster Epinephrine Delivery Compared to EpiPen with Accelerated Speed to Therapeutic Threshold (GlobeNewswire) -38.00%
Mar-09-26 08:30AM	Nasus Pharma to Present Topline Analysis from NS002 Intranasal Epinephrine Powder Phase 2 Single and Repeat Dose Clinical Study (GlobeNewswire) -15.43%
08:00AM	Nasus Pharma to Present and Participate in the Upcoming Life Sciences Investor Forum (GlobeNewswire)
Feb-20-26 08:00AM	Nasus Pharma to Participate in Upcoming Investor Conferences (GlobeNewswire) +18.00%
08:00AM	Loading…
Feb-17-26 08:00AM	Nasus Pharma to Present Data Highlighting Superior Nasal Deposition and Stability of Intranasal Epinephrine Powder at AAAAI 2026 (GlobeNewswire)
Feb-13-26 08:00AM	Nasus Pharma Announces Closing of $15.0 Million Private Placement (GlobeNewswire) +5.36%
Feb-10-26 11:03PM	Nasus Pharma Announces Pricing of $15.0 Million Private Placement (GlobeNewswire)
Jan-20-26 08:00AM	Nasus Pharma Announces Positive Interim Results from Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder (GlobeNewswire) -7.52%
Dec-22-25 08:00AM	Nasus Pharma CEO Issues 2025 Letter to Shareholders (GlobeNewswire) -6.56%
Nov-20-25 08:15AM	Nasus Pharma Strengthens Leadership Team, Appointing Eyal Rubin as Executive Vice President and Chief Financial Officer (GlobeNewswire)
Nov-18-25 08:00AM	Nasus Pharma Announces Initiation of Phase 2 Clinical Study of NS002 with First Participant Dosed (GlobeNewswire)
Nov-06-25 08:00AM	Nasus Pharma Announces Approval from Health Canada to Initiate Planned Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder (GlobeNewswire)
Sep-02-25 08:00AM	Nasus Pharma Announces Upcoming Presentation at H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-26-25 08:00AM	Nasus Pharma Marks NYSE American Listing with Bell Ringing Ceremony (GlobeNewswire)
04:05PM	Loading…
Aug-14-25 04:05PM	Nasus Pharma Announces Closing of Initial Public Offering (GlobeNewswire)
Aug-13-25 07:30AM	Nasus Pharma Announces Pricing of $10 Million Initial Public Offering (GlobeNewswire)

Nasus Pharma Ltd. engages in the development of intranasal drugs for emergency medical conditions. It offers Powder-Based Intranasal (PBI) specialized product portfolio, to address acute medical conditions and public health threats. The company was founded by Udi Gilboa and Dalia Megiddo in May 2019 and is headquartered in Tel Aviv, Israel.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Teleman Dan Benjamin	Chief Executive Officer	Mar 31 '26	Buy	2.04	15,000	30,600	21,246	Apr 01 07:31 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NSRX

Nasus Pharma Ltd

Upgrade your Finviz experience